PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial
BOTHELL, Wash. & TOKYO–(BUSINESS WIRE)– Seagen Inc. (Nasdaq: SGEN) and Astellas Pharma Inc. (TSE:4503) announced positive topline results from the Phase 3 EV-302 clinical trial (also known as KEYNOTE-A39) for PADCEV® (enfortumab… Read More



